Skip to main content
Premium Trial:

Request an Annual Quote

GE Inks Personalized Medicine Deal with Celera Genomics, Celera Diagnostics

NEW YORK, July 12 (GenomeWeb News) - General Electric said today that its GE Global Research unit has formed a joint research collaboration with Celera Genomics and Celera Diagnostics to discover and develop new products for personalized medicine.


Under the arrangement, GE said, the companies will work to understand and differentiate diseases at the molecular level. The first project outlined in the collaboration is designed to advance GE's efforts to develop novel imaging agents for cancer that selectively target cell surface proteins Celera Genomics has found to be associated with malignancies.


GE will have exclusive access to certain selected protein targets for research and development of imaging agents, the company said. All three companies will share certain responsibilities and costs associated with research and development, as well as value from commercial products resulting from the project, GE added.


GE, Celera Genomics, and Celera Diagnostics have also established a second project under their collaboration that focuses on the development of new algorithms and tools that advance the diagnostics and/or therapeutic programs of each company. New project agreements related to other disease areas, or tools that help create enabling technology and products may be added in the future, GE said.


Additional terms of the joint research collaboration were not disclosed.


The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.